Shuimu Molecule
水木分子
Shuimu Molecule (水木分子) is an AI-driven drug discovery company incubated out of Tsinghua University's Institute for AI Industry Research (AIR), founded and led as chief scientist by Professor Nie Zaiqing — a Tsinghua chair professor and AIR chief researcher who previously served as chief scientist of Tmall Genie at Alibaba and principal researcher at Microsoft Research Asia . It is a Dalton Venture (道彤投资) portfolio company, backed as part of Dalton's AI-for-science bets alongside its healthcare positions . The company runs what a 2026 Dalton interview calls a "dual-wheel" model: on one side, self-developed pipelines — starting with an autoimmune indication where its ChatDD platform computationally designed bispecific antibody candidates, with Dr. Pan Qi joining as Chief Scientific Officer for biopharmaceuticals; on the other, tool empowerment through products like the ChatDD drug R&D agent, the open-source BioMedGPT multimodal model, OpenBioMed Skills (45 launch skills covering biochemistry, protein design, and single-cell omics), and a consumer-facing life-sciences "intelligence assistant," Shuimu Zhile . Per that same Dalton piece, it reported 30+ brand partnerships, order growth above 100% year-on-year in 2025, and early overseas traction in East Asia as of May 2026 . One caution: it is a different company from Shuimu Biosciences (水木未来), the cryo-EM structural drug discovery platform that raised an angel round from Gaorong and others in 2020 — similar name, different entity .
AI-generated — may contain errors, please verify.
Coverage
Dalton Venture Wins Eight Awards from Joy List, Touzijia and Qimingpian for Biotech, AI Medical Breakthroughs, Innovative Devices, Life Sciences, Best Early-Stage Investment Institution and Healthcare Investment Institution
Recently, the winners of three major rankings were announced: the 10th Healthcare Investment Excellence Awards, the **Touzijia** 2025–2026 Fund Partner Rankings, and the Qimingpian 2026 Mid-Year China Equity Investment Rankings. Across the three lists, **Ning Huang, founding partner of Dalton Venture, was named to the Best Early-Stage Investor TOP 25, while Dalton Venture was recognized as Best Biotech Investment Firm, Best AI Healthcare Breakthrough Investment Firm, Best Innovative Medical Devices and Life Sciences Investment Firm, and...
When AI Starts Doing Science: A Recap of the SSCI Leading Fund × Dalton Venture Tong Academy Event
Scientific exploration has no end point, and innovation in the age of intelligence has only just begun.
Exclusive Interview with Professor Nie Zaiqing: Is the Biopharma Version of "AI Lobster" Here? Shuimu Molecular's Dual-Wheel Model of "Proprietary Pipeline + Tool Empowerment" | Tong's Family
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Dalton Venture's Sun Qi: Focus, Steady Rhythm, Multiple Paths — Actively Positioning Through the Cycle | Dalton Insights
On July 3–4, 2025, **the 19th China Fund Partners Conference, co-hosted by Zero2IPO and PEDaily, was held in Shanghai**. This year's gathering brought together capital leaders to discuss industry trends, examine the latest dynamics in China's LP market, and explore the path forward for venture capital in a new cycle. **Dalton Venture founding and managing partner Sam Sun was invited to join the roundtable forum *"Cycle Positioning, Investment Strategies"*** to exchange views with fellow guests on the evolution of investment cycles and responsive strategies.
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
